ClinicalTrials.gg
Status unknownNCT04924296Updated Jun 11, 2021

A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis

A Phase 2 interventional study of SHR-1314 and Placebo in Lupus Nephritis, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To demonstrate the efficacy of SHR-1314 at Week 12 in subjects with proliferation lupus nephritis in terms of improvement of 24h UPCR, compared to placebo. The study will also assess the safety and tolerability of SHR-1314 in the patient population over the study period.

02

Conditions studied

  • Lupus Nephritis

Browse trials for

03

In context

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

This study's planned enrollment of 60 is above the median of 48 across 243 interventional studies indexed under Lupus Nephritis.

Browse Lupus Nephritis studies →

Lead sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd. is the lead sponsor of 104 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese adult pts (18-65yr), Male or Female
  2. ≥18 kg/m2 and ≤ 35kg/m2
  3. Confirmed diagnosis of LN, renal report data is within 3-months prior to the date of ICF is first signed

    3.1 Biopsy-proven proliferative lupus nephritis Class III or Class IV, either with or without the presence of Class V, using the 2003 ISN/RPS criteria.

    3.2 24h UPCR ≥ 1 at screening.

    3.3 24h UPR ≥ 1.0 g/d,≤ 3.5 g/d.

    3.4 > 45ml/min/1.73m2.

  4. SLEDAI-2K≥8.

Exclusion criteria

Exclusion Criteria:

  1. Significant medical Problems like myocarditis, pericarditis, severe manifestations of neuropsychiatric SLE (NPSLE)
  2. Subjects who have previously treated by both CYC and MMF (or other forms of mycophenolate)
  3. With a hHistory of using 60 mg/d prednisolone (or equivalent dose) for more than 3 months prior to Baseline
  4. History of inflammatory bowel disease or have other ongoing active diseases
  5. Required management of acute or chronic infections within the past 8 weeks.
  6. At screening, history or symptoms of of any organ system, treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  7. History of congestive heart failure ( [NYHA] functional classification ≥III), cerebro-cardiovascular events, or serious bleeding events at screening and / or randomization that in the judgement of the Investigator prevents the subject from participating in the study.
  8. History of depression and/or suicidal ideation or any suicidal behavior based on an assessment using the Columbina Suicide Severity Rating Scale (C-SSRS) at screening and baseline . The subjects will be exluded if any answer to question is "yes" in the questionnaire orare clinically judged by the investigator to be at risk for suicide
  9. Receipt of any IL-17/IL-17R targeted therapy within the past year.
  10. Those who have participated in any clinical study for any drug or medical device within 3 months before screening.
  11. Tested positive for (HIV), , or .
  12. All subjects will be tested for tuberculosis status using IGRA and X-ray test. Subjects with active or latent tuberculosis will be excluded
  13. History of severe allergic reaction to contrast agents or biological medicines.Current drug or alcohol abuse or dependence.
  14. History of severe allergic reaction to contrast agents or biological medicines.Current drug or alcohol abuse or dependence.
  15. Pregnant or nursing..
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR-1314

  • Placebo comparator
    Treatment group B

    Drug: Placebo

Interventions

  • SHR-1314 s.c. + Steroids

  • DrugPlacebo

    Placebo s.c. + Steroids

06

What researchers measure

Primary outcomes

  1. percentage change of 24 hours UPCR from baseline to Week 12.

    Time frame: at 12 weeks

Secondary outcomes

  1. Percentage change of 24 hours UPCR from baseline to Week 24

    Time frame: from baseline to Week 24

  2. Percentage change of 24 hours UPCR from Week 12 to Week24

    Time frame: from Week 12 to Week24

  3. Percentage of participants achieving 24h UPCR <0.5 g/g at Week 12 and Week 24

    Time frame: at Week 12 and Week 24

  4. Percentage of participants achieving renal Complete Response at Week 12 and Week 24

    Time frame: at Week 12 and Week 24

  5. Percentage of pts achieving renal Partial Response at Week 12 and Week 24

    Time frame: at Week 12 and Week 24

  6. Change in PGA from baseline to Week 12 and Week 24

    Time frame: from baseline to Week 12 and Week 24

  7. Change in SLEDAI-2K from baseline to Week 12 and Week 24

    Time frame: from baseline to Week 12 and Week 24

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2021; primary completion for Dec 2021, 5 months later.

Of 33 phase 2 interventional studies under Lupus Nephritis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 57. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2021
First posted
Jun 11, 2021
StartEst.
Jun 28, 2021
Primary completionEst.
Dec 25, 2021
CompletionEst.
Sep 3, 2022
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04924296
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Jun 28, 2021 (estimated)
Primary completion
Dec 25, 2021 (estimated)
Completion
Sep 3, 2022 (estimated)
Last update
Jun 11, 2021

Study contacts

Yuxian Zhu, M.M
Contact
yuxian.zhu@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vunakizumab

Start the discussion